NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

December 16, 2024

Study Completion Date

December 20, 2024

Conditions

Wound HealWound Healing Disturbance ofWound Healing DisorderWound Healing DelayedDiabetic Foot UlcerDiabetic Foot Ulcer Mixed

Interventions

BIOLOGICAL

ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2

Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.

BIOLOGICAL

ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2

Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.

BIOLOGICAL

Placebo

Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).

Trial Locations (2)

Department of Endocrinology, Skåne University Hospital, Lund

Clinical Diabetes Research Unit at Uppsala University Hospital, Uppsala